TWI553120B - 艾杜糖醛酸鹽－２－硫酸酯酶之純化 - Google Patents

艾杜糖醛酸鹽－２－硫酸酯酶之純化 Download PDF

Info

Publication number
TWI553120B
TWI553120B TW102123353A TW102123353A TWI553120B TW I553120 B TWI553120 B TW I553120B TW 102123353 A TW102123353 A TW 102123353A TW 102123353 A TW102123353 A TW 102123353A TW I553120 B TWI553120 B TW I553120B
Authority
TW
Taiwan
Prior art keywords
protein
purified recombinant
recombinant
composition
seq
Prior art date
Application number
TW102123353A
Other languages
English (en)
Chinese (zh)
Other versions
TW201410868A (zh
Inventor
戴夫 尼可拉斯
Original Assignee
舒爾人類基因療法公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI553120(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 舒爾人類基因療法公司 filed Critical 舒爾人類基因療法公司
Publication of TW201410868A publication Critical patent/TW201410868A/zh
Application granted granted Critical
Publication of TWI553120B publication Critical patent/TWI553120B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW102123353A 2012-06-29 2013-06-28 艾杜糖醛酸鹽－２－硫酸酯酶之純化 TWI553120B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (2)

Publication Number Publication Date
TW201410868A TW201410868A (zh) 2014-03-16
TWI553120B true TWI553120B (zh) 2016-10-11

Family

ID=49778401

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102123353A TWI553120B (zh) 2012-06-29 2013-06-28 艾杜糖醛酸鹽－２－硫酸酯酶之純化
TW105120026A TWI587869B (zh) 2012-06-29 2013-06-28 艾杜糖醛酸鹽-２-硫酸酯酶之純化

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105120026A TWI587869B (zh) 2012-06-29 2013-06-28 艾杜糖醛酸鹽-２-硫酸酯酶之純化

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP2867245B1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN104583225A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA2877517C (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY192068A (enExample)
NZ (3) NZ743910A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871B1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI553120B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
BR112019003622A2 (pt) 2016-08-25 2019-05-21 Jcr Pharmaceuticals Co., Ltd. método para produção de uma proteína de fusão.
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
KR20230088811A (ko) * 2020-10-23 2023-06-20 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
EP2325302B1 (en) 2003-02-11 2016-01-06 Shire Human Genetic Therapies, Inc. Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
KR20080111487A (ko) 2006-03-20 2008-12-23 메다렉스, 인코포레이티드 단백질 정제 방법
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
ES2643015T3 (es) * 2010-06-25 2017-11-21 Shire Human Genetic Therapies, Inc. Tratamiento del Síndrome de Sanfilippo Tipo B
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Also Published As

Publication number Publication date
PH12020500027A1 (en) 2021-03-15
NZ733366A (en) 2019-12-20
PH12015502408A1 (en) 2018-03-26
JP2015523072A (ja) 2015-08-13
TR201815811T4 (tr) 2018-11-21
LT2867245T (lt) 2018-11-12
MX2015000190A (es) 2015-04-08
JP2018121645A (ja) 2018-08-09
PL2867245T3 (pl) 2019-02-28
NZ743910A (en) 2019-12-20
AR091647A1 (es) 2015-02-18
US20240043817A1 (en) 2024-02-08
US20210317426A1 (en) 2021-10-14
AU2013282395B2 (en) 2015-12-03
CO7240396A2 (es) 2015-04-17
JP2016119911A (ja) 2016-07-07
SG11201408761VA (en) 2015-01-29
KR101380740B1 (ko) 2014-04-11
EA202090044A1 (ru) 2020-07-31
WO2014005014A2 (en) 2014-01-03
WO2014005014A3 (en) 2014-02-27
IL261264A (en) 2018-10-31
AU2018200230A1 (en) 2018-02-01
US11530393B2 (en) 2022-12-20
MY192068A (en) 2022-07-25
TWI587869B (zh) 2017-06-21
US20170073652A1 (en) 2017-03-16
IL248727A0 (en) 2017-01-31
PH12014502871A1 (en) 2015-02-23
US12359178B2 (en) 2025-07-15
SI2867245T1 (sl) 2018-12-31
TW201703794A (zh) 2017-02-01
CN107596358A (zh) 2018-01-19
MX366906B (es) 2019-07-30
MX336715B (es) 2016-01-28
CN104583225A (zh) 2015-04-29
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
JP2020105209A (ja) 2020-07-09
PH12015502408B1 (en) 2020-02-14
BR112014032567B1 (pt) 2022-09-13
MX393364B (es) 2025-03-19
CA3008945A1 (en) 2014-01-03
MX2019008914A (es) 2019-09-26
PH12014502871B1 (en) 2015-02-23
CA2877517C (en) 2018-07-31
KR20140004603A (ko) 2014-01-13
HRP20181897T1 (hr) 2019-01-11
US20150313972A1 (en) 2015-11-05
PE20150720A1 (es) 2015-05-16
KR20140002451A (ko) 2014-01-08
JP6171007B2 (ja) 2017-07-26
ES2689468T3 (es) 2018-11-14
US9492511B2 (en) 2016-11-15
HUE040769T2 (hu) 2019-03-28
AU2013282395A1 (en) 2015-01-29
US20140004096A1 (en) 2014-01-02
EP3441398A1 (en) 2019-02-13
SMT201800612T1 (it) 2019-01-11
US20240401010A1 (en) 2024-12-05
UA121959C2 (uk) 2020-08-25
AU2013282395C1 (en) 2016-03-24
RS58005B1 (sr) 2019-02-28
US20190359958A1 (en) 2019-11-28
EP2867245A2 (en) 2015-05-06
US10344270B2 (en) 2019-07-09
AU2018200230B2 (en) 2020-01-02
CA2877517A1 (en) 2014-01-03
IL236315A (en) 2016-11-30
HK1249026A1 (zh) 2018-10-26
DOP2014000294A (es) 2015-03-15
KR20200143339A (ko) 2020-12-23
EP2867245B1 (en) 2018-09-12
HK1249027A1 (zh) 2018-10-26
GT201400303A (es) 2017-08-31
CN107596357A (zh) 2018-01-19
IL287057A (en) 2021-12-01
MY180287A (en) 2020-11-27
JP6505629B2 (ja) 2019-04-24
PT2867245T (pt) 2018-11-26
EP2867245A4 (en) 2016-03-09
IL236315A0 (en) 2015-02-26
IL261264B (en) 2021-10-31
AU2016200469B2 (en) 2017-10-12
NZ703093A (en) 2017-08-25
EA201492177A1 (ru) 2015-06-30
DK2867245T3 (en) 2018-11-26
JP7594365B2 (ja) 2024-12-04
CL2014003567A1 (es) 2015-04-24
AU2016200469A1 (en) 2016-02-18
US9051556B2 (en) 2015-06-09
MY157087A (en) 2016-04-19
SG10201703489VA (en) 2017-05-30
CY1121519T1 (el) 2020-05-29
ZA201409397B (en) 2019-10-30
UA129561C2 (uk) 2025-06-04
TW201410868A (zh) 2014-03-16
KR20190064542A (ko) 2019-06-10
BR112014032567A2 (pt) 2017-08-01
KR20220002227A (ko) 2022-01-06
ZA201803289B (en) 2021-04-28
HK1209431A1 (en) 2016-04-01
EA034549B1 (ru) 2020-02-19

Similar Documents

Publication Publication Date Title
TWI553120B (zh) 艾杜糖醛酸鹽－２－硫酸酯酶之純化
HK1209767B (en) Purification of iduronate-2-sulfatase